FADS2 and steatosis: When challenged with a mild dose of FFAs (320 μM), FADS2−/− organoids displayed a markedly aggravated steatosis phenotype compared with FADS2WT organoids challenged with the same FFA dose (Fig. 6c,d), further strengthening the evidence of an important role for FADS2 in balancing lipid homeostasis.